Targeting NEBL via a siRNA-loaded nanocarrier for advanced non-small cell lung cancer treatment

Introduction: NEBL has been recently identified as an oncogene in NSCLC, facilitating tumor metastasis, invasion, and progression. However, the role of NEBL in drug resistance and immune modulation remains elusive.
DNA hypermethylation plays a crucial role in tumor progression by silencing tumor suppressor and immune-related genes. Azacitidine (Aza) is an effective DNA methyltransferase inhibitor (DNMTi), but it only shows limited efficacy in solid tumors. Our RNA-seq shows that Aza upregulates Nebl, suggesting that targeting Nebl could boost Aza therapy in NSCLC.